Immunotherapy combo could open door to liver transplant for more cancer patients

NCT ID NCT07489976

First seen Apr 06, 2026 · Last updated Apr 29, 2026 · Updated 2 times

Summary

This study tests whether combining immunotherapy with a liver-directed procedure can safely shrink liver cancer (hepatocellular carcinoma) enough to make patients eligible for a liver transplant. About 41 adults whose cancer is too advanced for current transplant criteria will receive the combination therapy. Researchers will track how many patients' tumors shrink to transplant-eligible size within 12 months and monitor side effects closely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cedars Sinai

    RECRUITING

    Los Angeles, California, 90048, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.